Published in Neuro Oncol on October 01, 2005
Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev (2008) 2.27
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Gene expression changes with age in skin, adipose tissue, blood and brain. Genome Biol (2013) 1.34
Embryonic frog epidermis: a model for the study of cell-cell interactions in the development of mucociliary disease. Dis Model Mech (2010) 1.15
The spatial organization of proton and lactate transport in a rat brain tumor. PLoS One (2011) 1.05
Regulation and function of aquaporin-1 in glioma cells. Neoplasia (2007) 1.01
Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer (2008) 0.93
Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic Acids Res (2010) 0.91
GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol (2007) 0.89
Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol (2012) 0.89
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer (2010) 0.85
Elucidation of how cancer cells avoid acidosis through comparative transcriptomic data analysis. PLoS One (2013) 0.81
The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo. Int J Mol Sci (2014) 0.80
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma. J Cancer (2015) 0.79
Interaction of HIF-1α and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells. Genes Cancer (2013) 0.78
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature (1998) 4.03
Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem (1995) 3.22
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer (1985) 2.59
Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene (1994) 2.45
Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis (1996) 2.44
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics (1996) 2.34
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A (1998) 2.20
Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol (2001) 2.15
Biological consequences of tumor hypoxia. Semin Oncol (2001) 2.11
Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol (1998) 2.11
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol (1998) 1.99
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology (1982) 1.99
Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res (1997) 1.96
The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell (1995) 1.91
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol (1994) 1.69
Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem (1998) 1.57
Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A (2000) 1.55
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res (2001) 1.55
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med (1992) 1.50
The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol (2003) 1.44
Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res (2001) 1.41
Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer (2000) 1.37
Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? Bioorg Med Chem (2001) 1.37
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol (1999) 1.22
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J (1999) 1.20
The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun (2001) 1.18
The cellular physiology of carbonic anhydrases. JOP (2001) 1.07
In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol (1992) 1.00
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology (2002) 0.99
In vivo measurement of brain tumor pH using [11C]DMO and positron emission tomography. Ann Neurol (1985) 0.97
In vivo measurement of regional brain tissue pH using positron emission tomography. Ann Neurol (1984) 0.93
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res (2001) 0.92
Carbonic anhydrase (CA)-related proteins (CA-RPs), and transmembrane proteins with CA or CA-RP domains. EXS (2000) 0.92
Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers. Proc Natl Acad Sci U S A (2000) 0.91
pH distributions in transplanted neural tumors and normal tissues of BDIX rats as measured with pH microelectrodes. Cancer Res (1982) 0.91
Close similarity between receptor-linked tyrosine phosphatase and rat brain proteoglycan. Cell (1994) 0.90
Human primary brain tumour metabolism in vivo: a phosphorus magnetic resonance spectroscopy study. Br J Cancer (1989) 0.90
The descriptive epidemiology of brain tumors. Neuroimaging Clin N Am (1999) 0.88
Metabolism of the malignant astrocytoma. Neurosurgery (1990) 0.87
In vivo measurement of regional brain and tumor pH using [14C]dimethyloxazolidinedione and quantitative autoradiography. J Cereb Blood Flow Metab (1985) 0.86
Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model. Clin Exp Metastasis (1999) 0.85
P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. Biochim Biophys Acta (2000) 0.84
Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res (1997) 0.82
Vascular endothelial growth factor (vascular permeability factor) expression in injured rat brain. J Neurosci Res (1997) 0.81
Introduction to the carbonic anhydrases. EXS (2000) 0.81
Lactate metabolism conducted by rat C6-glioma in the cells culture. J Neurosurg Sci (1994) 0.77
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
von Hippel-Lindau disease. Lancet (2003) 6.20
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery--a feasibility study. Acta Neurochir (Wien) (2013) 3.41
Prevention of intraoperative cerebrospinal fluid leaks by lumbar cerebrospinal fluid drainage during surgery for pituitary macroadenomas. J Neurosurg (2012) 3.35
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Posterior subtemporal transtentorial approach to intraparenchymal lesions of the anteromedial region of the superior cerebellum. J Neurosurg (2005) 2.69
Pathophysiology of persistent syringomyelia after decompressive craniocervical surgery. Clinical article. J Neurosurg Spine (2010) 2.49
Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA (2005) 2.47
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation (2007) 2.46
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg (2003) 2.34
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades 0-2 nonfunctioning pituitary macroadenomas at a single institution. J Neurosurg (2014) 2.13
The variability of atlas-based targets in relation to surrounding major fibre tracts in thalamic deep brain stimulation. Acta Neurochir (Wien) (2014) 2.04
Awake craniotomies without any sedation: the awake-awake-awake technique. Acta Neurochir (Wien) (2013) 2.02
Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine (2012) 1.92
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA (2007) 1.73
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg (2007) 1.68
Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg (2011) 1.64
Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg (2009) 1.61
Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2006) 1.58
CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol (2008) 1.56
Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg (2006) 1.55
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Fluorescein sodium-guided resection of cerebral metastases—experience with the first 30 patients. Acta Neurochir (Wien) (2015) 1.55
Intraoperative infrared functional imaging of human brain. Ann Neurol (2003) 1.54
Strigolactone biosynthesis in Medicago truncatula and rice requires the symbiotic GRAS-type transcription factors NSP1 and NSP2. Plant Cell (2011) 1.52
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Slit3 inhibits activator protein 1-mediated migration of malignant melanoma cells. Int J Mol Med (2011) 1.49
Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg (2003) 1.48
A nodule-specific protein secretory pathway required for nitrogen-fixing symbiosis. Science (2010) 1.46
Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab (2003) 1.44
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res (2005) 1.41
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40
Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med (2004) 1.38
The history of pituitary surgery for Cushing disease. J Neurosurg (2011) 1.38
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res (2003) 1.38
Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg (2002) 1.35
TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res (2006) 1.35
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol (2002) 1.35
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol (2006) 1.34
Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res (2006) 1.34
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg (2005) 1.31
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg (2003) 1.30
Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol (2008) 1.27
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg (2008) 1.26
Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab (2005) 1.24
Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res (2006) 1.23
Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.23
Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol (2005) 1.23
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res (2010) 1.22
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol (2004) 1.22
Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.21
Pathophysiology of headache associated with cough in patients with Chiari I malformation. J Neurosurg (2003) 1.20
Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer (2004) 1.19
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One (2011) 1.19
When should conservative treatment for lumbar disc herniation be ceased and surgery considered? Neurosurg Rev (2002) 1.18
Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 1.18
Transient increase of ATP as a response to temperature up-shift in Escherichia coli. Microb Cell Fact (2005) 1.18
Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg (2004) 1.17
Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg (2005) 1.17
Effect of ependymal and pial surfaces on convection-enhanced delivery. J Neurosurg (2008) 1.17
N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 1.17
Image-guided convection-enhanced delivery of gemcitabine to the brainstem. J Neurosurg (2007) 1.17
Durable broad-spectrum powdery mildew resistance in pea er1 plants is conferred by natural loss-of-function mutations in PsMLO1. Mol Plant Pathol (2011) 1.16
Human ISWI chromatin-remodeling complexes sample nucleosomes via transient binding reactions and become immobilized at active sites. Proc Natl Acad Sci U S A (2010) 1.15
Medicago N2-fixing symbiosomes acquire the endocytic identity marker Rab7 but delay the acquisition of vacuolar identity. Plant Cell (2009) 1.13
Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg (2005) 1.13
Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters. Mol Ther (2012) 1.13
THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene (2005) 1.12
Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab (2009) 1.11
Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res (2005) 1.11
Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg (2007) 1.11
Salvage therapy in patients with glioblastoma: is there any benefit? Cancer (2003) 1.11
Pituitary stalk hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2009) 1.10
Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin Chim Acta (2008) 1.10
Ascorbate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. J Cell Biochem (2006) 1.10
Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res (2005) 1.09
Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene (2005) 1.08
Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol (2005) 1.08
The usefulness of the awake-awake-awake technique. Acta Neurochir (Wien) (2014) 1.08
Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res (2003) 1.08
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res (2005) 1.07
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res (2008) 1.07
Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci (2007) 1.06
Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2008) 1.06